Glucocorticoids (GCs) can act as stress hormones and modulate multiple, seemingly unrelated phenotypic and psychological traits, including mood and other emotional behaviors (Holsboer and Ising, 2010) . Produced in the adrenal gland and secreted into the bloodstream, GCs oscillate in a daily manner, and their levels peak at the beginning of the activity phase (that is, in the morning for humans and in the evening for laboratory rodents). When GC oscillations are perturbed, misregulation of the dependent biological processes is expected. However, it remains unknown whether specific features of these oscillations (period length, amplitude, and phase) are causally linked to specific behaviors. In this issue, Ikeda et al. (2013) propose that variations in the daily amplitude of GC levels influence anxiolytic behavior in mice. The underlying mechanism may rely on the hypothalamic-pituitary-adrenal (HPA) axis, the major driver of GC oscillations, and on paracrine signaling within the adrenal gland mediated by the opioid peptide BAM22 and its receptor CXCR7 (Figure 1) .
The HPA axis controls GC production in the adrenal gland and its secretion into the bloodstream through a cascade of peptide hormones. Stimulated by the hypothalamic hormone corticotropin releasing factor (CRF), the pituitary secretes adrenocorticotropic hormone (ACTH), which activates the G-protein-coupled receptor melanocortin 2 receptor (MC2R) in the adrenal cortex. The resulting intracellular signaling cascade promotes GC synthesis. Once secreted, GCs establish a negative-feedback loop in the hypothalamus and the pituitary gland by inhibiting the production of CRF and the secretion of ACTH. This feedback loop and neuroendocrine connections between the suprachiasmatic nucleus (SCN) and CRF-producing cells in the hypothalamus (Vrang et al., 1995) are thought to be responsible for the daily oscillations of GCs (Dickmeis, 2009; Kino, 2011) . In some cases, however, stress factors and the associated physiological challenges introduce some plasticity in plasma GC concentrations. Imagine that you wake up in the middle of the night several days in a row because your cat keeps jumping on your bed. Every time it happens, the adrenal gland produces bursts of GCs, and with time, the adrenal gland develops a thicker cortex. This adaptive reaction of the adrenal gland is known as subcapsular cell hyperplasia (SCH).
Initially identified as a lesion, SCH is histologically different from tumors and is considered a common outcome of adrenal tissue remodeling during aging (Aiba and Fujibayashi, 2011) . However, a physiological role for SCH has not been proposed thus far. Ikeda et al. observed that mice with SCH have a normal period length and phase of GC secretion, combined with an unperturbed responsiveness to stress. However, in female mice the amplitudes of daily GC oscillations were increased at ZT12 (ZT: Zeitgeber Time, the time after the lights are switched on). Based on a battery of behavioral tests, the higher amplitudes were causally linked with enhanced anxiolytic effects. Notably, this phenomenon is not observed in SCH male mice, and the overconfidence of the female mice was no longer observed when GCs amplitudes were dampened using GC receptor inhibitors, in which case the scores of SCH females were reduced to the level observed in SCH males.
Like other steroid nuclear receptors, the GC receptor has gender-specific functions (Rando and Wahli, 2011) . But how does it make SCH females so brave? In answering this question, Ikeda et al. identify BAM22 and other opioid peptides expressed in the adrenal gland of SCH mice. Since subcapsular hyperplastic cells express both the prohormone proenkephalin A and the corresponding convertase furin, it is possible that opioids are synthesized in situ and act as paracrine factors for glucocorticoid-producing cells (Figure 1 ). Consistent with this conjecture, SCH mice with homozygous loss of the proenkephalin A gene do not display an improved score in anxiety tests. Moreover, in adrenal cell cultures, BAM22 activates the CXCR7 protein-G-coupled receptor, leading to an increased GC output. Interestingly, the phenotype is exacerbated in cells treated concomitantly with BAM22 and ACTH, suggesting a synergistic effect between the opioid and ACTH pathways. Finally, in SCH female mice the stimulation of CXCR7 signaling with CCX771, a long-lived CXCR7 receptor agonist, augmented the daily amplitude of GC plasma levels and affected the associated anxiolytic behavior in a coherent manner. As anticipated, SCH male mice showed a blunted response because CXCR7 was not efficiently expressed in their adrenal cortex. Thus, tissue remodeling occurring during SCH may generate paracrine peptides that regulate GC amplitudes in addition to the HPA axis ( Figure 1) .
As is always the case with papers reporting provocative findings, this study raises a myriad of exciting issues remaining to be addressed by future work. For instance, it is still unclear whether CXCR7 signaling oscillates in a diurnal fashion. Similarly, it remains to be determined whether CXCR7 modulates plasma GC concentrations by regulating their synthesis, stability, or secretion. As hypothesized by the authors, the narrow time window during which BAM22 enhances GC accumulation may insinuate the involvement of local circadian clocks in the adrenal cortex. If true, it would be interesting to further elucidate the molecular interplay between clock components and CXCR7 signaling. One general theme of this study is the cooperation between acute signaling and ''hard-wired'' clock mechanisms in the regulation of cyclic physiological processes. In order to maintain phase coherence within a tissue, the cellular circadian oscillators must be regularly synchronized by systemic cues emanating from the master circadian pacemaker in SCN. In the case of the adrenal gland, neuronal and nonneuronal pathways have been shown to be operative in this endeavor (Ishida et al., 2005) . The Zeitgeber properties of plasma GCs for peripheral circadian oscillators (Balsalobre et al., 2000; Pezü k et al., 2012) opens the exciting possibility that these steroid hormones may determine their own amplitude in the blood by participating in the synchronization of the HPA axis, local clocks in the adrenal gland, and, as a consequence, the paracrine signaling described here by Ikeda and colleagues-resonating waves add up! In female mice, subcapsular hyperplasic cells (SCH) express proenkephalin A, which can be converted to active opioid peptides by the processing enzyme furin. Once in the portal plexus, opioid peptides activate the chemochine receptor CXCR7, which is expressed mainly in females, and promote glucocorticoid (GC) synthesis, probably through a mitogen activated protein kinase (MAPK) cascade. The CXCR7 axis aligns in phase with the HPA axis because only the amplitude, but not the other parameters, of GC oscillation is modulated by the opioid peptide BAL22. Enhanced GC amplitudes are causally related to anxiolytic performance through an undefined mechanism.
